Literature DB >> 35737148

Nephroprotective Effect of Leu-Ile-Lys Tripeptide in Experimental Diabetes Mellitus.

G V Zharikova1, A Yu Zharikov2, O N Mazko2, O G Makarova2, I P Bobrov2, A S Kalnitsky2.   

Abstract

We studied the effect of tripeptide Leu-Ile-Lys on kidney function in rats with experimental diabetes mellitus modeled by single intraperitoneal administration of streptozotocin (65 mg/kg). The tripeptide was intragastrically administrated in a dose of 11.5 mg/kg from week 5 to week 8 of the pathological process. The concentrations of glucose, protein, and creatinine in the urine were measured before and then weekly throughout the experiment. In 8 weeks, the markers of activity of the free radical oxidation process (concentration of TBA-reactive substances, total prooxidant activity, and total antioxidant activity, as well as activities of catalase, superoxide dismutase, and glutathione peroxidase) were assayed and a morphological study was conducted. After administration of the tripeptide Leu-Ile-Lys for 4 weeks, glucose concentration in the urine decreases by 3-44 times (p<0.001) and protein concentration by 2.3-3.7 times (p=0.007). The concentration of TBA-reactive substances decreased by 1.3 times (p<0.001), and the total antioxidant activity increased by 2.3 times (p<0.001). Administration of the tripeptide Leu-Ile-Lys to animals with experimental diabetes mellitus led to significant improvement of the renal function against the background of significant alleviation of oxidative damage and an increase in the antioxidant protection of the renal tissues. Improvement of the morphofunctional state of tissues and cells of the renal glomerulus was confirmed histologically, in particular, an increase in the number of podocytes by 1.5 times was observed.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  diabetes mellitus; kidney function; tripeptide Leu-Ile-Lys

Mesh:

Substances:

Year:  2022        PMID: 35737148     DOI: 10.1007/s10517-022-05520-4

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  7 in total

Review 1.  The Role of Dietary Antioxidants on Oxidative Stress in Diabetic Nephropathy.

Authors:  Francisco Gerardo Yanowsky-Escatell; Jorge Andrade-Sierra; Leonardo Pazarín-Villaseñor; Christian Santana-Arciniega; Eduardo De Jesús Torres-Vázquez; Jonathan Samuel Chávez-Iñiguez; Miguel Ángel Zambrano-Velarde; Francisco Martín Preciado-Figueroa
Journal:  Iran J Kidney Dis       Date:  2020-03       Impact factor: 0.892

Review 2.  Glomerular podocytes in diabetic renal disease.

Authors:  Paweł Podgórski; Andrzej Konieczny; Łukasz Lis; Wojciech Witkiewicz; Zbigniew Hruby
Journal:  Adv Clin Exp Med       Date:  2019-12       Impact factor: 1.727

Review 3.  Assessment of lipid peroxidation by measuring malondialdehyde (MDA) and relatives in biological samples: Analytical and biological challenges.

Authors:  Dimitrios Tsikas
Journal:  Anal Biochem       Date:  2016-10-24       Impact factor: 3.365

4.  Experience of Using Tripeptide Leu-Ile-Lys for Experimental Therapy of Chronic 16-Week Oxalate Nephrolithiasis in Rats.

Authors:  A Yu Zharikov; N N Yakushev; O N Mazko; O G Makarova; A V Lepilov; I P Bobrov; G V Zharikova; V I Kiselev
Journal:  Bull Exp Biol Med       Date:  2020-07-10       Impact factor: 0.804

5.  Effect of Tripeptide Leu-Ile-Lys on the Course of Experimental Nephrolithiasis.

Authors:  A Yu Zharikov; N N Yakushev; G V Zharikova; O N Mazko; O G Makarova; A V Lepilov; I P Bobrov
Journal:  Bull Exp Biol Med       Date:  2019-10-26       Impact factor: 0.804

Review 6.  Diabetes mellitus statistics on prevalence and mortality: facts and fallacies.

Authors:  Paul Zimmet; K George Alberti; Dianna J Magliano; Peter H Bennett
Journal:  Nat Rev Endocrinol       Date:  2016-07-08       Impact factor: 43.330

Review 7.  Drug Targets for Oxidative Podocyte Injury in Diabetic Nephropathy.

Authors:  Adnan Bashir Bhatti; Muhammad Usman
Journal:  Cureus       Date:  2015-12-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.